AnaptysBio (ANAB) Competitors $15.99 -0.66 (-3.96%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ANAB vs. WVE, MIRM, AKRO, AMPH, IRON, TARS, CGON, HRMY, GLPG, and XNCRShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), Amphastar Pharmaceuticals (AMPH), Disc Medicine (IRON), Tarsus Pharmaceuticals (TARS), CG Oncology (CGON), Harmony Biosciences (HRMY), Galapagos (GLPG), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Amphastar Pharmaceuticals Disc Medicine Tarsus Pharmaceuticals CG Oncology Harmony Biosciences Galapagos Xencor Wave Life Sciences (NASDAQ:WVE) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility and risk, WVE or ANAB? Wave Life Sciences has a beta of -1.21, indicating that its stock price is 221% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Does the media refer more to WVE or ANAB? In the previous week, AnaptysBio had 33 more articles in the media than Wave Life Sciences. MarketBeat recorded 39 mentions for AnaptysBio and 6 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 1.44 beat AnaptysBio's score of 0.20 indicating that Wave Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Wave Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 6 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer WVE or ANAB? Wave Life Sciences currently has a consensus target price of $22.22, indicating a potential upside of 53.79%. AnaptysBio has a consensus target price of $45.09, indicating a potential upside of 181.99%. Given AnaptysBio's higher probable upside, analysts clearly believe AnaptysBio is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community believe in WVE or ANAB? AnaptysBio received 3 more outperform votes than Wave Life Sciences when rated by MarketBeat users. However, 67.85% of users gave Wave Life Sciences an outperform vote while only 66.06% of users gave AnaptysBio an outperform vote. CompanyUnderperformOutperformWave Life SciencesOutperform Votes36367.85% Underperform Votes17232.15% AnaptysBioOutperform Votes36666.06% Underperform Votes18833.94% Which has preferable valuation and earnings, WVE or ANAB? Wave Life Sciences has higher earnings, but lower revenue than AnaptysBio. Wave Life Sciences is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWave Life Sciences$53.61M41.11-$57.51M-$1.11-13.02AnaptysBio$57.17M8.51-$163.62M-$6.08-2.63 Is WVE or ANAB more profitable? Wave Life Sciences has a net margin of -66.50% compared to AnaptysBio's net margin of -289.75%. Wave Life Sciences' return on equity of -280.57% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Wave Life Sciences-66.50% -280.57% -52.90% AnaptysBio -289.75%-287.94%-37.25% Do institutionals and insiders believe in WVE or ANAB? 89.7% of Wave Life Sciences shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by company insiders. Comparatively, 33.7% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryWave Life Sciences beats AnaptysBio on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyHiding in the Bible New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$486.56M$6.86B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-2.6310.75130.2217.53Price / Sales8.51287.791,246.14139.51Price / CashN/A56.6541.2337.95Price / Book4.825.394.884.92Net Income-$163.62M$152.04M$119.65M$225.78M7 Day Performance3.09%-4.32%16.62%-1.56%1 Month Performance-15.31%2.80%16.34%6.68%1 Year Performance-18.63%17.30%35.38%22.48% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.3992 of 5 stars$15.99-4.0%$45.09+182.0%-16.9%$486.56M$57.17M-2.63100Short Interest ↑Analyst RevisionHigh Trading VolumeWVEWave Life Sciences4.9155 of 5 stars$13.59+1.1%$22.22+63.5%+227.7%$2.07B$113.31M-12.11240Positive NewsMIRMMirum Pharmaceuticals4.1801 of 5 stars$42.38-0.1%$57.73+36.2%+22.1%$2.03B$307.03M-21.01140AKROAkero Therapeutics3.958 of 5 stars$29.09+0.7%$46.83+61.0%+33.6%$2.03BN/A-7.7030Short Interest ↓AMPHAmphastar Pharmaceuticals4.8642 of 5 stars$41.25-2.3%$60.33+46.3%-27.8%$1.98B$644.40M14.081,761Insider TradeIRONDisc Medicine3.4259 of 5 stars$66.64+2.7%$87.50+31.3%+10.7%$1.98BN/A-16.3078TARSTarsus Pharmaceuticals0.5337 of 5 stars$51.86-1.2%$54.20+4.5%+179.6%$1.98B$17.45M-13.7850Positive NewsCGONCG Oncology2.0459 of 5 stars$28.54-0.8%$63.88+123.8%N/A$1.93B$684,000.000.0061Insider TradeHRMYHarmony Biosciences4.7533 of 5 stars$32.78+1.2%$47.00+43.4%-0.1%$1.87B$681.88M15.35200Analyst ForecastShort Interest ↓News CoverageGLPGGalapagos0.74 of 5 stars$27.00+0.7%$30.75+13.9%-31.6%$1.78B$260.09M0.001,123XNCRXencor4.1914 of 5 stars$25.12+4.5%$36.56+45.5%+19.7%$1.76B$168.34M-7.51280 Related Companies and Tools Related Companies Wave Life Sciences Competitors Mirum Pharmaceuticals Competitors Akero Therapeutics Competitors Amphastar Pharmaceuticals Competitors Disc Medicine Competitors Tarsus Pharmaceuticals Competitors CG Oncology Competitors Harmony Biosciences Competitors Galapagos Competitors Xencor Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANAB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
